Emmaus Life Sciences, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503
Mailing Address
21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE, CA, 90503
Phone
310-214-0065
Fiscal Year End
1231
EIN
870419387
Financial Overview
FY2025
$2.13M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 31, 2026 | View on SEC |
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 8-K Current report of material events | December 22, 2025 | View on SEC |
| 8-K Current report of material events | December 19, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 14, 2025 | View on SEC |
| 8-K Current report of material events | August 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Strategic shift to a licensing model for Endari with NeoImmuneTech
- Significant reduction in operating expenses from $26.4M to $19.8M
Material Events
8-K
Financial Distress
March 31, 2026
High Impact
- First positive operating profit achieved through aggressive 34% cost reduction
- Strategic pivot toward international markets in the Middle East and North Africa
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.